St Patrick's Mental Health Services website uses cookies. By continuing to browse the site you are agreeing to our use of cookies. For more details about cookies and how to manage them see our cookie policy.

Anxiety disorders in adolescents

With adolescents all over the country just finished their Leaving and Junior Cert exams, Consultant Psychiatrist in Willow Grove Adolescent Unit at St Patrick’s Mental Health Services, discusses management of anxiety presentations in primary care.

Epidemiology and course of paediatric anxiety disorders:

Anxiety disorders are the most frequent psychiatric disorders in children and adolescents, affecting between 15 – 20% of youth (Kessler et al., 2012). Anxiety disorders in youths are associated with increased morbidity and mortality and an increased risk of suicide attempts (Foley et al 2006; Jacobsen et al., 2008).  Longitudinal data suggest that young people with anxiety disorders are three times more likely to have anxiety or depression in adult life (Pine et al., 1998), they are also at increased risk of substance misuseChild and adolescent anxiety disorders are linked with poorer long-term general health and functioning, as well as interpersonal, financial and educational difficulties (Woodward et al, 2001). Early and effective treatment may help prevent continuity of psychopathology into adulthood.

There is considerable heterogeneity in the onset of specific anxiety disorders, with GAD, phobic anxiety, panic disorder and OCD mostly emerging in adolescence (Wehry et al., 2015). 

Diagnostic classification:

  • Generalised anxiety disorder (GAD) (ICD - 10, F41.1): GAD is characterised by chronic, excessive worry in a number of areas such as schoolwork, social interactions, family, health/safety, world events. Children with GAD have trouble controlling their worries, they are often perfectionistic, show high reassurance seeking and may struggle with more internal distress than is evident to others.  Symptoms are generally present most days for at least several weeks, and usually for several months and there is associated impairment in social functioning. Symptoms include worry or apprehension, muscular tension, fatigue, poor concentration, irritability and sleep disturbance. 
  • Social phobia (F 40.1) is characterised by feeling scared of uncomfortable in one or more social settings or performance situations. The discomfort is associated with social scrutiny and the fear of doing something embarrassing. These individuals may have difficulty eating in public, answering questions in class, reading aloud, initiating conversations, talking with unfamiliar people and attending parties or social events. A fear of vomiting in public may be present.  Social phobias are usually associated with low self-esteem and fear of criticism. Avoidance is marked and may result in significant social isolation. Unlike most other phobias, social phobias are equally common in men and women. 
  • Agoraphobia (F 40.0) refers to an interrelated and often overlapping cluster of phobias embracing fears of leaving home, where there is difficulty of immediate escape to a safe place. The anxiety must occur mainly in at least two of the following situations; crowds, public places, travelling away from home or travelling alone.
  • Panic Disorder (F 41.0) includes essential features of recurrent attacks of severe anxiety/panic which are not restricted to any particular set of circumstances and are unpredictable. Symptoms vary from person to person, but include palpitations, chest pain, choking sensation, dizziness, feelings of unreality (depersonalisation/ derealisation). Psychological fears of losing control, dying or “going mad” may be present. A crescendo of autonomic symptoms often results in an exit from the situation and subsequent avoidance, which re-enforces the underlying anxiety.

Neurobiology of paediatric anxiety:

There have been significant advances in the understanding of the neurobiology of childhood anxiety disorders in recent times, with dysfunction in the pre-frontal amygdala-based circuits being widely implicated (Strawn et al, 2014).  The amygdala, responsible for the initiation of the fear response, is often “over-activated” in fMRI.  Intrinsic functional connectivity networks between the amygdala and the pre-frontal cortex, anterior cingulate cortex, insula and cerebellum have also been implicated.  The ventrolateral pre-fontal cortex (VLPFC), which regulates amygdala activity and plays a role in the extinction of the fear response, is also hyperactivated in youths with anxiety (Blackford et al., 2012).

Differential diagnosis:

Differentials that can mimic the symptoms of anxiety include attention deficit hyperactivity disorder (ADHD) (restlessness, inattention); autism spectrum disorder (ASD) (social awkwardness, social skills and communication deficits); learning difficulties (persistent worries about school performance); depression (difficulties with sleep, inattention, somatic complaints); and bipolar disorder (irritability, insomnia, restlessness). Anxiety may also be mimicked by a range of physical health conditions including endocrine abnormalities (hyperthyroidism, hypoglycaemia, pheochromocytoma); neurological disorders (migraine, epilepsy, brain tumours), cardiovascular (arrhythmias); medications including steroids, anti-asthmatics and sympathomimetics. Selective serotonin reuptake inhibitors (SSRIs) can cause anxiety symptoms in addition to caffeine, energy drinks and some over-the-counter/internet-bought medicines including anti-histamines, cold medicines and diet pills.

The anxiety cycle

Screening and assessment:

Practice parameters from the American Academy of Child and Adolescent Psychiatry (AACAP) recommend screening for anxiety symptoms, noting the severity and functional impairment and assessing for co-morbidity.  Screening for general medical conditions that may mimic anxiety is also recommended. Evaluation should differentiate from developmentally appropriate worries and fears, and should consider stressors or traumas that may be contributing to the anxiety.  Anxiety-related symptoms such as crying, irritability or anger outbursts, which are sometimes misinterpreted by adults as oppositionality or disobedience, may represent the young person’s distress and efforts to avoid the anxiety-provoking stimulus.        

Treatment:

AACAP guidelines suggest multimodal treatment including psychoeducation, psychotherapy (eg. Cognitive behavioural therapy (CBT) and pharmacotherapy.  Family support/family therapy is often useful depending on parental anxiety, parenting style and attachment patterns, family problem solving and familial relationships. Pharmacotherapy is recommended for moderate to severe anxiety symptoms.

The Childhood Anxiety Multimodal Study (CAMS), involved 488 youths aged 7-17 years. This study showed that monotherapy with sertraline (55% response) is as effective as CBT for anxiety (60% response) compared with placebo (24% response), and that a combination of sertraline and CBT is most likely to be successful (81% response). Some 80% of acute responders maintained their positive response at follow-up (24 and 36 weeks). Six-year naturalistic follow up of this group suggested that results were maintained with remission rates of 52% (sertraline only), 49% (combination therapy), and 46% (CBT only).  Nearly half of responders had relapsed during the follow-up period suggesting that extended treatment is needed to maintain treatment gains (Piacentini et al., 2014).

Pharmacotherapy

SSRIs are the medications of choice for the treatment of anxiety disorders in children and adolescents. A summary of randomised controlled trials of SSRIs in treating anxiety disorders in youths indicates that the benefits outweigh the risks for most SSRIs (sertraline, fluoxetine, fluvoxamine and paroxetine), there is insufficient data for the remaining SSRIs and the serotonin and norepinephrine reuptake inhibitors (SNRI) desvenlafaxine (Garland et al., 2016). For Venlafaxine XR, one publication showed positive results but lower effect sizes than SSRIs and significantly higher adverse effects compared to placebo (Rynn et al., 2007). The number needed to treat for most SSRIs and SNRIs over placebo is estimated between three and six (Bridge et al., 2007). 

Sertraline and fluoxetine have been approved by the Food and Drug Administration) (FDA) for the treatment of paediatric OCD and are first-line treatments for anxiety.  SNRIs could be considered a third-line treatment for anxiety disorders when two trials with different SSRIs prove ineffective.

Adverse effects of medications:

Physical side-effects of SSRIs include headaches, gastric upset, insomnia, hypersomnia.  Emotional/behavioural effects include hyperactivity, irritability dis-inhibition and self-harm (Elbe et al., 2014). The FDA issued a black box warning in 2004 for concerns related to worsening of depression, agitation and suicidal ideation linked to SSRIs.  Studies report one excess case of suicidal ideation or self-harm per 100 treated individuals with anxiety compared to placebo, and two excess cases of suicidal ideation or self-harm per 100 treated individuals with depression compared to placebo (Hammad et al., 2006). However, overall SSRI treatment significantly decreases suicidal ideation and suicide attempts in young people and it is far more likely that SSRI use decreases suicide rates rather than increases them (Mosholder et al., 2004).

The efficacy and safety of buspirone and mirtazapine in young people with anxiety disorders are not known, although open label studies suggest that they might be effective in relieving anxiety symptoms. Benzodiazepine use is not supported by clinical trials in youths and may lead to paradoxical disinhibition. Rarely, benzodiazepine use can be considered in practice to potentiate the therapeutic effect during initial titration of SSRIs or to mitigate adverse effects, and for rapid tranquillisation.

As a general rule when prescribing in adolescents, start at the lowest available dose and monitor closely, usually within a week or two of starting treatment.  Dose increases are done cautiously and with careful monitoring, overall therapeutic effect should appear within six to eight weeks of treatment.  Medications, if effective, should continue for at least one year of stable improvement. Tapering of medications, when indicated, should also be done slowly to minimise the risk of discontinuation symptoms.

Psychotherapy

CBT is a well-regarded and effective evidence-based treatment for child and adolescent anxiety disorders (Compton et al., 2004). CBT has several key components including psychoeducation, somatic skills training (relaxation, breathing exercise), cognitive restructuring by challenging anxiety-provoking thoughts and negative self-talk, problem solving; systematic exposure and desensitisation to the feared situation; relapse prevention (Albano et al., 2002).  A number of studies have also shown benefit of group CBT in youths with anxiety (Barrett et al., 1998). CBT is not effective for all youths with anxiety disorders, a portion may continue to meet criteria for an anxiety disorder after treatment.

Although often used, evidence for psychodynamic psychotherapy for youth anxiety is sparse and more studies are needed. Mindfulness has been increasingly used recently to promote health and wellbeing, Randomised controlled trials in anxious adults show significant improvement in anxiety symptoms (Hoge et al., 2013). Studies of mindfulness-based interventions are more limited in children and adolescent however this represents an area that warrants further investigation.

Management in primary care

Mild cases of anxiety can usually be treated in the community with psychoeducation and individual psychological intervention, for example CBT, depending on locally available resources.  Factors that influence referral to specialist adolescent mental health services include illness severity, co-morbidity, risk management, positive family history or family dysfunction. Medications can be used for people presenting with a moderate to severe level of impairment in conjunction with individual therapy.

 

Author

Dr Una Dennison

Dr Una Dennison, MB BAO BCh MRCPsych MD is a Consultant Child and Adolescent Psychiatrist working with St. Patricks Mental Health Service since June 2018 following relocation from London where she worked with the NHS as a Consultant Child and Adolescent Psychiatrist.  Dr Dennison has experience working with young people and their families across a wide variety of settings including both out-patient, inpatient and liaison CAMHS.  She has experience leading a Neuro-Developmental / Learning Disability Team in the UK. Dr Dennison has a special interest in inpatient adolescent psychiatry and adolescent eating disorders and has spent time working in a specialist adolescent eating disorders unit at the Priory Hospital, London.  She has also worked in Sydney, Australia.

She has a strong teaching background, having spent 18 months working as a clinical lecturer / tutor in psychiatry in University College Cork and has experience teaching a mixture of audiences at both under-graduate and post-graduate level, including post-graduate, medical and secondary school students, allied health professionals and GP’s. She completed a Masters Degree by Research on immune dysfunction in schizophrenia and bipolar disorder and has several publications relevant to this field.

Publications:

Dennison U., Dinan T., 2012. “Schizophrenia patients with a history of childhood trauma have a pro-inflammatory phenotype”.  Psychological Medicine Feb 2012, 23: 1-7
Dennison U., Dinan T., 2012. “Menstrual Cycle influences toll-like receptor responses”. Neuroimmunomodulation 19: 171 – 179
Dennison U., Cassidy E., 2011. “The clinical correlates of lithium toxicity – a retrospective review”.  Irish Journal of Medical Science Vol 180; No 3, 661 – 665
Mc Kernan D., Dennison U., Dinan T., “Enhanced peripheral toll-like receptor responses in psychosis: further evidence of a pro-inflammatory phenotype”.  Translational Psychiatry Aug 2011: 1(8); e36.

She is a member of the Royal College of Psychiatrists UK as well as the College of Psychiatry of Ireland and is fully compliant with CPD requirements.

Continue to…

Founder’s Day 2019 to focus on anxiety

Support & Information

We provide free support and information for GP's and healthcare professionals regarding services available in St Patrick's.

01 249 3333

Sign up to our GP eNewsletter

Sign up to our quarterly GP eNewsletter to receive information about mental health, service updates, events & CPD training at St Patrick’s Mental Health Services. Please be advised, this eNewsletter cannot be delivered to @healthmail email addresses. Please provide an alternative email address.